文献类型：期刊文献

英文题名：Enhanced γ-Glutamyltranspeptidase Imaging That Unravels the Glioma Recurrence in Post-radio/Chemotherapy Mixtures for Precise Pathology via Enzyme-Triggered Fluorescent Probe

作者：Shi, Ben[1,2];Zhang, Zhenyu[1,2];Lan, Chuanjin[3];Wang, Bao[3];Xu, Shangchen[4];Ge, Mingxu[4];Xu, Ge[1,2];Zhu, Tianli[1,2];Liu, Yingchao[4];Zhao, Chunchang[1,2]

机构：[1]East China Univ Sci & Technol, Sch Chem & Mol Engn, Key Lab Adv Mat, Shanghai, Peoples R China;[2]East China Univ Sci & Technol, Sch Chem & Mol Engn, Inst Fine Chem, Shanghai, Peoples R China;[3]Shandong Univ, Sch Med, Jinan, Shandong, Peoples R China;[4]Shandong Univ, Shandong Prov Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China

年份：2019

卷号：13

外文期刊名：FRONTIERS IN NEUROSCIENCE

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000470213600002)】；

基金：We gratefully acknowledge the financial support from the National Natural Science Foundation of China (Grant Nos. 21672062, 21574044, and 81641176), the 2016 National Key Research and Development Program (2016YFC0106105), the Taishan Scholars Program (No. tsqn20161070), and the Natural Science Foundation of Shandong Province (ZR2019HM067).

语种：英文

外文关键词：biomarker; gamma-glutamyltranspeptidase; fluorescent probe; glioma recurrence; pathological diagnosis

摘要：Accurate pathological diagnosis of gliomas recurrence is crucial for the optimal management and prognosis prediction. The study here unravels that our newly developed gamma-glutamyltranspeptidase (GGT) fluorescence probe (Figure 1A) imaging in twenty recurrent glioma tissues selectively recognizes the most malignant portion from treatment responsive tissues induced by radio/chemo-therapy (Figure 1B). The overexpression of GGT in recurrent gliomas and low level in radiation necrosis were validated by western blot analysis and immunohistochemistry. Furthermore, the ki-67 index evaluation demonstrated the significant increase of malignancy, aided by the GGT-responsive fluorescent probe to screen out the right specimen through fast enhanced imaging of enzyme activity. Importantly, our GGT-targeting probe can be used for accurate determination of pathologic evaluation of tumor malignancy, and eventually for guiding the following management in patients with recurrent gliomas.